EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector

Se Jin Kim iD, Ganesh M Mugundu iD, Aman P Singh iD

Clinical and Translational Science · 2024-12 · 17 (12)

DOI: 10.1111/cts.70101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 18.12.2024. Verfasst von Se Jin Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Cell Therapy and Therapeutic Area Unit, Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Takeda Pharma…. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Development Center Americas, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous chimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable response rates, yet its widespread implementation is hindered by logistical, financial, and physical constraints. Additionally, challenges such as poor persistence and allorejection are associated with allogeneic cell therapies. An innovative approach involves in vivo transduction of endogenous T‐cells through the administration of CAR mRNA encapsulated in polymeric nanoparticles (NPs), resulting in transient CAR surface expression on circulating T‐cells. This method presents a promising alternative, although the dose–exposure–response relationship of in vivo CAR‐Ts remains poorly elucidated. The transient nature of CAR expression may necessitate repeated dosing, potentially introducing additional hurdles like cost and patient compliance. To address this issue, we have devised a translational pharmacokinetic–pharmacodynamic (PK–PD) model that characterizes the transient surface CAR expression following mRNA‐encapsulated NP administration, leveraging in vitro and in vivo data alongside critical binding kinetic parameters sourced from literature. Our model adequately captures the transient surface CAR expression in both settings, while incorporating known physiological parameter values and exhibiting precise estimation of unknown parameters (coefficient of variation < 30%). Global sensitivity analyses underscore the significance of intracellular mRNA stability, highlighting the sensitivity of parameters linked to free intracellular mRNA concentration. Model‐based simulations indicate that optimizing dose and dosing frequency can achieve sustained CAR expression, despite the transient protein expression characteristic of mRNA‐based therapies. This mechanistic PK–PD model holds potential for integration into physiologically‐based pharmacokinetic models, facilitating the translation of in vivo CAR‐T‐cell therapies from preclinical studies to human applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesRNA, MessengerImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansPolymersAnimalsTranslational Research, BiomedicalModels, Biological

Substanzen

RNA, MessengerReceptors, Chimeric AntigenPolymers

Autor:innen und Institutionen

  • Oncology Cell Therapy and Therapeutic Area Unit, Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.

ORCID-Profile: Se Jin Kim, Ganesh M Mugundu, Aman P Singh

Förderung

  • Takeda Development Center Americas, Inc

Zitieren

APA

Kim, S. J., Mugundu, G. M., & Singh, A. P. (2024). Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector. Clinical and Translational Science, 17(12). https://doi.org/10.1111/cts.70101

Vancouver

Kim SJ, Mugundu GM, Singh AP. Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector. Clinical and Translational Science. 2024;17(12). doi:10.1111/cts.70101

BibTeX
@article{Kim2024,
  author = {Kim, Se Jin and Mugundu, Ganesh M and Singh, Aman P},
  title = {Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {12},
  doi = {10.1111/cts.70101}
}
Kostenlos starten →